SCHEMBL12360742

SCHEMBL12360742

Cc1cnc2nc(-c3c(F)cccc3Cl)c(Nc3ccc4c(c3)OCCO4)n2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 17/20 0.51
▸ GAA P10253 15/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ TP53 P04637 4/20 0.47
▸ HTT P42858 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2253789 0.89 GAA (0.53) MAPTGAATDP1CYP1A2CYP3A4
SCHEMBL2252362 0.86 MAPT (0.65) MAPTGAATDP1SMN1; SMN2ALDH1A1
SCHEMBL2253450 0.85 MAPT (0.51) MAPTGAATDP1SMN1; SMN2ALDH1A1
SCHEMBL2250466 0.85 GAA (0.69) MAPTGAATDP1CYP1A2CYP3A4
SCHEMBL12360744 0.84 GAA (0.48) MAPTGAATDP1CYP1A2CYP3A4
SCHEMBL2251686 0.82 MAPT (0.65) MAPTGAATDP1SMN1; SMN2ALDH1A1
SCHEMBL2252072 0.80 GAA (0.62) MAPTGAATDP1CYP1A2CYP3A4
SCHEMBL14016031 0.80 MAPT (0.70) MAPTGAATDP1SMN1; SMN2ALDH1A1
SCHEMBL12376237 0.80 MAPT (0.45) MAPTGAATDP1CYP1A2CYP3A4
SCHEMBL2252270 0.80 MAPT (0.55) MAPTGAATDP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS CNR1, CNR2, GPR18 MAPT 2915/4885GAA 4087/4885TDP1 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback